Hims & Hers Health (NYSE:HIMS) Releases Earnings Results, Misses Expectations By $0.32 EPS

Hims & Hers Health (NYSE:HIMS) issued its quarterly earnings data on Monday. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.32), FiscalAI reports. The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.89 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business’s revenue for the quarter was up 38.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.17 earnings per share.

Here are the key takeaways from Hims & Hers Health’s conference call:

• Revenue and subscriber growth accelerated. Q2 revenue rose nearly 40% year over year to more than $753 million, with 300,000 net new subscribers bringing the total to nearly 3 million; management raised full-year 2026 revenue guidance to $3.1 billion–$3.3 billion.
• The company reported early benefits from its AI-native care platform, including three times more customer messaging, an approximately 50% reduction in non-clinical support tasks, and lower cancellation rates in pilot cohorts. Management expects AI investments to pay back within 12–18 months and support improved retention and cost efficiency.
• International expansion is becoming a major growth driver following the Eucalyptus acquisition. International revenue increased more than 17-fold year over year to $131 million, and the company expects international revenue of at least $600 million in 2026 while expanding U.S. specialties such as testosterone, sexual health, and dermatology overseas.
• New growth opportunities include injectable and oral testosterone before year-end and peptide-related wellness offerings, subject to regulatory developments. The company expects to launch already permitted offerings such as sermorelin, glutathione, and NAD+ by year-end, while awaiting final FDA rulemaking for additional peptides.
• Profitability and cash flow faced near-term pressure from the business mix and one-time costs. Adjusted gross margin fell to 64% as branded weight-loss products and international revenue grew, Q2 free cash flow was negative $68 million, and the company incurred approximately $81 million in acquisition, restructuring, and FTC-related legal costs; management also said international operations may remain near breakeven as it invests for scale.

Hims & Hers Health Trading Down 2.6%

NYSE:HIMS traded down $0.84 during mid-day trading on Tuesday, reaching $30.93. The company’s stock had a trading volume of 23,025,973 shares, compared to its average volume of 26,800,920. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.69 and a quick ratio of 1.56. The stock has a market cap of $7.16 billion, a P/E ratio of -343.66, a P/E/G ratio of 88.90 and a beta of 2.40. The company’s fifty day simple moving average is $31.94 and its two-hundred day simple moving average is $26.07. Hims & Hers Health has a twelve month low of $13.74 and a twelve month high of $65.30.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the transaction, the chief operating officer owned 432,124 shares of the company’s stock, valued at $13,611,906. This trade represents a 3.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David B. Wells purchased 48,400 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was bought at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the acquisition, the director owned 224,417 shares in the company, valued at $5,437,623.91. The trade was a 27.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have sold 83,126 shares of company stock worth $2,711,339. Corporate insiders own 11.76% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Brooklyn Investment Group lifted its stake in shares of Hims & Hers Health by 124.7% in the 3rd quarter. Brooklyn Investment Group now owns 4,405 shares of the company’s stock valued at $250,000 after purchasing an additional 2,445 shares in the last quarter. Centaurus Financial Inc. increased its position in Hims & Hers Health by 26.0% during the 3rd quarter. Centaurus Financial Inc. now owns 4,312 shares of the company’s stock worth $245,000 after purchasing an additional 889 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. acquired a new stake in Hims & Hers Health during the 2nd quarter worth approximately $234,000. SkyView Investment Advisors LLC purchased a new position in Hims & Hers Health in the second quarter valued at approximately $226,000. Finally, Kovack Advisors Inc. purchased a new position in Hims & Hers Health in the fourth quarter valued at approximately $216,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HIMS has been the topic of a number of analyst reports. Barclays increased their price objective on Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research note on Wednesday, June 17th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. TD Cowen upped their target price on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday. Citigroup decreased their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a research note on Tuesday. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Hims & Hers Health in a report on Friday. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $32.43.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Second-quarter revenue rose 38% year over year to $753.2 million, exceeding analysts’ expectations of approximately $699 million. Strong subscriber growth and broader personalized-care offerings supported the result. Hims & Hers raises annual forecast revenue on strong subscriber growth
• Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, while third-quarter revenue guidance of $880 million-$900 million also topped consensus. Management cited AI-driven engagement, specialty care expansion and international growth through Eucalyptus. HIMS Q2 Earnings Call Focuses on AI and Global Expansion
• Positive Sentiment: Needham raised its price target from $35 to $42 and maintained a “buy” rating, pointing to potential upside if the company’s growth investments translate into improved profitability. Needham price target update
• Neutral Sentiment: Bank of America increased its target from $30 to $32 but retained a “neutral” rating, indicating limited near-term upside at recent trading levels. Bank of America price target update
• Negative Sentiment: The company reported a quarterly loss of approximately $0.37 per share, substantially worse than the roughly $0.05 expected loss. Restructuring charges and investments related to branded GLP-1 weight-loss treatments and international expansion pressured profitability and reduced gross margin. Hims & Hers shares slide as costly weight-loss push squeezes margins
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations or alleged fiduciary-duty breaches involving Hims & Hers directors and officers. These announcements do not establish wrongdoing but add headline and litigation risk for shareholders. Kaplan Fox investigation announcement

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.